Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
821 participants
INTERVENTIONAL
2003-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization
NCT05395351
Combined Treatment With Alteplase (Rt-PA) and Cerebrolysin® in Acute Ischemic Hemispheric Stroke
NCT00840671
Thrombectomy Under Reopro Versus Alteplase to Treat Stoke
NCT02016547
1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients
NCT05395338
Alteplase Treatment in Elderly Acute Ischaemic Stroke (AIS) Patients
NCT05401149
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
rt-PA 0.9 mg/kg verum or placebo Intravenous
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age: 18 - 80 years.
* Clinical diagnosis of ischemic stroke causing a measurable neurological deficit defined as impairment of language, motor function, cognition and/or gaze, vision or neglect. Ischemic stroke is defined as an event characterized by the sudden onset of an acute focal neurologic deficit presumed to be due to cerebral ischemia after CT scan excludes hemorrhage.
* Onset of symptoms between 3 and 4 hours prior to initiation of administration of study drug.
* Stroke symptoms are to be present for at least 30 minutes and have not significantly improved before treatment. Symptoms must be distinguishable from an episode of generalized ischemia (i.e. syncope), seizure, or migraine disorder.
* Patient is willing to participate voluntarily and to sign a written patient informed consent. Informed consent will be obtained from each patient or the subject's legally authorized representative or relatives, or deferred where applicable, according to the regulatory and legal requirements of the participating country.
* Patients who are unable to sign but who are able to understand the meaning of participation in the study may give an oral witnessed informed consent. These patients have to make clear undoubtfully that they are willing to participate voluntarily and must be able to understand an explanation of the contents of he information sheet.
* Willingness and ability to comply with the protocol.
Exclusion Criteria
* Symptoms of ischaemic attack began more than 4 hours and 30 minutes prior to infusion start or when time of symptom onset is unknown.
* Minor neurological deficit or symptoms rapidly improving before start of infusion.
* Severe stroke as assessed clinically (e.g. NIHSS\>25) and/or by appropriate imaging techniques.
* Epileptic seizure at onset of stroke
* Symptoms suggestive of subarachnoid haemorrhage, even if the CT-scan is normal.
* Administration of heparin within the previous 48 hours and a thromboplastin time exceeding the upper limit of normal for laboratory
* History of prior stroke and concomitant diabetes. \* Prior stroke within the last 3 months
* Platelet below 100,000/mm3. \* Systolic blood pressure \>185 mmHg or diastolic blood pressure \>110 mmHg, or aggressive management (IV medication) necessary to reduce BP to these limits.
* Blood glucose \<50 or \> 400 mg/dl (\< 2.77 or \> 22.15 mmol / l). \* Known haemorraghic diathesis
* Patients receiving oral anticoagulants. \* Manifest or recent severe or dangerous bleeding
* Known history of or suspected intracranial haemorrhage
* Suspected subarachnoid haemorrhage or condition after subarachnoid haemorrhage from aneurysm
* History of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery)
* Haemorrhagic retinopathy,e.g. in diabetes (vision disturbances may indicate haemorrhagic retinopathy)
* Recent (less than 10 days) traumatic external heart massage, obstetrical delivery, recent puncture of a non-compressible blood-vessel (e.g. subclavian or jugular vein puncture.
* bacterial endocarditis, pericarditis.\* Acute pancreatitis
* Documented ulcerative gastrointestinal disease during the last 3 months, oesophageal varices, arterial- aneurysm, arterial/venous malformation
* Neoplasm with increased bleeding risk
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boehringer Ingelheim
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Boehringer Ingelheim
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Boehringer Ingelheim
Role: STUDY_CHAIR
Boehringer Ingelheim
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
135.312.43004 Boehringer Ingelheim Investigational Site
Graz, , Austria
135.312.43007 Boehringer Ingelheim Investigational Site
Innsbruck, , Austria
135.312.43010 Boehringer Ingelheim Investigational Site
Klagenfurt, , Austria
135.312.43001 Boehringer Ingelheim Investigational Site
Linz, , Austria
135.312.43012 Boehringer Ingelheim Investigational Site
Linz, , Austria
135.312.43013 Boehringer Ingelheim Investigational Site
Linz, , Austria
135.312.43008 Boehringer Ingelheim Investigational Site
Ma.Gugging/Klosterneuburg, , Austria
135.312.43006 Boehringer Ingelheim Investigational Site
Salzburg, , Austria
135.312.43003 Boehringer Ingelheim Investigational Site
Sankt Pölten, , Austria
135.312.43002 Boehringer Ingelheim Investigational Site
Vienna, , Austria
135.312.32006 O.L. Vrouwziekenhuis
Aalst, , Belgium
135.312.32002 Boehringer Ingelheim Investigational Site
Anderlecht, , Belgium
135.312.32014 Boehringer Ingelheim Investigational Site
Antwerp, , Belgium
135.312.32001 Boehringer Ingelheim Investigational Site
Bruges, , Belgium
135.312.32016 Boehringer Ingelheim Investigational Site
Godinne, , Belgium
135.312.32011 Boehringer Ingelheim Investigational Site
Kortrijk, , Belgium
135.312.32005 Boehringer Ingelheim Investigational Site
Leuven, , Belgium
135.312.42001 Boehringer Ingelheim Investigational Site
Ostrava, , Czechia
135.312.42004 Boehringer Ingelheim Investigational Site
Ostrava-Vitkovice, , Czechia
135.312.42002 Boehringer Ingelheim Investigational Site
Prague, , Czechia
135.312.45005 Boehringer Ingelheim Investigational Site
Aalborg, , Denmark
135.312.45002 Boehringer Ingelheim Investigational Site
Aarhus, , Denmark
135.312.45001 Boehringer Ingelheim Investigational Site
Copenhagen NV, , Denmark
135.312.45004 Boehringer Ingelheim Investigational Site
Glostrup Municipality, , Denmark
135.312.35801 Boehringer Ingelheim Investigational Site
Helsinki, , Finland
135.312.35805 Boehringer Ingelheim Investigational Site
Kuopio, , Finland
135.312.35802 Boehringer Ingelheim Investigational Site
Turku, , Finland
135.312.33009 Boehringer Ingelheim Investigational Site
Auch, , France
135.312.33016 Boehringer Ingelheim Investigational Site
Besançon, , France
135.312.33013 Boehringer Ingelheim Investigational Site
Bordeaux, , France
135.312.33017 Boehringer Ingelheim Investigational Site
Bourg-en-Bresse, , France
135.312.33008 Boehringer Ingelheim Investigational Site
Dijon, , France
135.312.33014 Boehringer Ingelheim Investigational Site
Grenoble Cédex 9, , France
135.312.33015 Boehringer Ingelheim Investigational Site
Lille, , France
135.312.33019 Boehringer Ingelheim Investigational Site
Limoges, , France
135.312.33001 Boehringer Ingelheim Investigational Site
Lyon, , France
135.312.33024 Boehringer Ingelheim Investigational Site
Mantes-la-Jolie, , France
135.312.33021 Boehringer Ingelheim Investigational Site
Meaux, , France
135.312.33002 Boehringer Ingelheim Investigational Site
Montpellier, , France
135.312.33004 Boehringer Ingelheim Investigational Site
Nancy, , France
135.312.33003 Boehringer Ingelheim Investigational Site
Nice, , France
135.312.33006 Boehringer Ingelheim Investigational Site
Paris, , France
135.312.33007 Boehringer Ingelheim Investigational Site
Paris, , France
135.312.33020 Boehringer Ingelheim Investigational Site
Pau, , France
135.312.33018 Boehringer Ingelheim Investigational Site
Perpignan, , France
135.312.33023 Boehringer Ingelheim Investigational Site
Pontoise, , France
135.312.33010 Boehringer Ingelheim Investigational Site
Saint-Herblain, , France
135.312.33005 Boehringer Ingelheim Investigational Site
Toulouse, , France
135.312.33012 Boehringer Ingelheim Investigational Site
Toulouse, , France
135.312.33011 Boehringer Ingelheim Investigational Site
Tours, , France
135.312.33022 Boehringer Ingelheim Investigational Site
Versailles, , France
135.312.49031 Boehringer Ingelheim Investigational Site
Altenburg, , Germany
135.312.49011 Boehringer Ingelheim Investigational Site
Bamberg, , Germany
135.312.49037 Boehringer Ingelheim Investigational Site
Beeskow, , Germany
135.312.49017 Boehringer Ingelheim Investigational Site
Bochum, , Germany
135.312.49008 Boehringer Ingelheim Investigational Site
Cologne, , Germany
135.312.49038 Boehringer Ingelheim Investigational Site
Frankfurt am Main, , Germany
135.312.49041 Boehringer Ingelheim Investigational Site
Hamburg, , Germany
135.312.49023 Boehringer Ingelheim Investigational Site
Hanover, , Germany
135.312.49001 Boehringer Ingelheim Investigational Site
Heidelberg, , Germany
135.312.49014 Boehringer Ingelheim Investigational Site
Leipzig, , Germany
135.312.49020 Boehringer Ingelheim Investigational Site
Ludwigshafen am Rhein, , Germany
135.312.49004 Boehringer Ingelheim Investigational Site
Magdeburg, , Germany
135.312.49003 Boehringer Ingelheim Investigational Site
Mainz, , Germany
135.312.49018 Boehringer Ingelheim Investigational Site
Mannheim, , Germany
135.312.49002 Boehringer Ingelheim Investigational Site
Minden, , Germany
135.312.49006 Boehringer Ingelheim Investigational Site
München, , Germany
135.312.49005 Boehringer Ingelheim Investigational Site
Siegen, , Germany
135.312.49025 Boehringer Ingelheim Investigational Site
Teupitz, , Germany
135.312.49009 Boehringer Ingelheim Investigational Site
Wiesbaden, , Germany
135.312.30004 Boehringer Ingelheim Investigational Site
Athens, , Greece
135.312.30005 Boehringer Ingelheim Investigational Site
Larissa, , Greece
135.312.30002 Boehringer Ingelheim Investigational Site
Thessaloniki, , Greece
135.312.36002 University of Debrecen
Debrecen, , Hungary
135.312.36001 Aladár Petz County Hospital
Győr, , Hungary
135.312.36006 BAZ County and Teaching Hospital
Miskolc, , Hungary
135.312.39020 Università degli Studi
Coppito (aq), , Italy
135.312.39013 A. O. Universitaria di Careggi
Florence, , Italy
135.312.39019 Ospedale Santa Maria Annunziata
Florence, , Italy
135.312.39022 Ospedale di Imperia
Imperia, , Italy
135.312.39024 Istituto Scientifico San Raffaele
Milan, , Italy
135.312.39002 A. O. di Padova - Policlinico Universitario
Padua, , Italy
135.312.39005 A. O. di Perugia - Policlinico Monteluce
Perugia, , Italy
135.312.39023 P. O. di Piacenza
Piacenza, , Italy
135.312.39016 A. O. Ospedale Santa Corona
Pietra Ligure (sv), , Italy
135.312.39006 Ospedale Santa Chiara
Pisa, , Italy
135.312.39003 A. O. Arcispedale "Santa Maria Nuova"
Reggio Emilia, , Italy
135.312.39001 A. O. Policlinico Umberto I
Roma, , Italy
135.312.39025 Università di Roma "La Sapienza"
Roma, , Italy
135.312.39018 Ospedale S. Maria della Misericordia
Udine, , Italy
135.312.39009 Ospedale Maggiore di BorgoTrento
Verona, , Italy
135.312.39004 Ospedale Civile
Vicenza, , Italy
135.312.31001
Amsterdam, , Netherlands
135.312.31007 Medisch Spectrum Twente
Enschede, , Netherlands
135.312.47001 Boehringer Ingelheim Investigational Site
Bergen, , Norway
135.312.47003 Boehringer Ingelheim Investigational Site
Trondheim, , Norway
135.312.47006 Boehringer Ingelheim Investigational Site
Tønsberg, , Norway
135.312.48004 Medical University of Gdansk
Gdansk, , Poland
135.312.48005 Dept. of Neurology, Regenerative and Cerebrovascular Disease
Katowice, , Poland
135.312.48006 Wojewodship Specialistic Neuropsychiatric Centre in Opole
Opole, , Poland
135.312.48001 Institute of Psychiatry & Neurology in Warsaw
Warsaw, , Poland
135.312.48002 Dr. Anna Gostynska Wolski Hospital
Warsaw, , Poland
135.312.35101 Hospitais da Universidade de Coimbra
Coimbra, , Portugal
135.312.35106 Hospital de Santa Maria
Lisbon, , Portugal
135.312.35102 Hospital de Santo António
Porto, , Portugal
135.312.35105 Hospital de São Sebastião, EPE
Santa Maria da Feira, , Portugal
135.312.42103 NEURON PLUS s.r.o
Bratislava, , Slovakia
135.312.42102 Hospital Levoca
Levoča, , Slovakia
135.312.42104 Jessenius Faculty of Medicine Commenius University
Martin, , Slovakia
135.312.42101 Faculty Hospital
Nitra, , Slovakia
135.312.42105 Boehringer Ingelheim Investigational Site
Trnava, , Slovakia
135.312.34019 Boehringer Ingelheim Investigational Site
Albacete, , Spain
135.312.34006 Boehringer Ingelheim Investigational Site
Badalona / Barcelona, , Spain
135.312.34001 Boehringer Ingelheim Investigational Site
Barcelona, , Spain
135.312.34002 Boehringer Ingelheim Investigational Site
Barcelona, , Spain
135.312.34003 Boehringer Ingelheim Investigational Site
Barcelona, , Spain
135.312.34011 Boehringer Ingelheim Investigational Site
Bilbao, , Spain
135.312.34007 Boehringer Ingelheim Investigational Site
Girona, , Spain
135.312.34009 Boehringer Ingelheim Investigational Site
Madrid, , Spain
135.312.34010 Boehringer Ingelheim Investigational Site
Madrid, , Spain
135.312.34020 Boehringer Ingelheim Investigational Site
Madrid, , Spain
135.312.34017 Boehringer Ingelheim Investigational Site
Santiago de Compostela, , Spain
135.312.34018 Boehringer Ingelheim Investigational Site
Seville, , Spain
135.312.34014 Boehringer Ingelheim Investigational Site
Zaragoza, , Spain
135.312.46007 Boehringer Ingelheim Investigational Site
Lidköping, , Sweden
135.312.46003 Boehringer Ingelheim Investigational Site
Malmo, , Sweden
135.312.46005 Boehringer Ingelheim Investigational Site
Skövde, , Sweden
135.312.46002 Boehringer Ingelheim Investigational Site
Stockholm, , Sweden
135.312.46004 Boehringer Ingelheim Investigational Site
Stockholm, , Sweden
135.312.41003 Boehringer Ingelheim Investigational Site
Aarau, , Switzerland
135.312.41001 Boehringer Ingelheim Investigational Site
Basel, , Switzerland
135.312.41004 Boehringer Ingelheim Investigational Site
Lausanne, , Switzerland
135.312.41002 Boehringer Ingelheim Investigational Site
Sankt Gallen, , Switzerland
135.312.44025 Boehringer Ingelheim Investigational Site
Aberdeen, , United Kingdom
135.312.44002 Boehringer Ingelheim Investigational Site
Bournemouth, , United Kingdom
135.312.44023 Boehringer Ingelheim Investigational Site
Cambridge, , United Kingdom
135.312.44026 Boehringer Ingelheim Investigational Site
Dundee, , United Kingdom
135.312.44003 Boehringer Ingelheim Investigational Site
Glasgow, , United Kingdom
135.312.44006 Boehringer Ingelheim Investigational Site
Glasgow, , United Kingdom
135.312.44024 Boehringer Ingelheim Investigational Site
Glasgow, , United Kingdom
135.312.44018 Boehringer Ingelheim Investigational Site
Liverpool, , United Kingdom
135.312.44030 Boehringer Ingelheim Investigational Site
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Alper BS, Foster G, Thabane L, Rae-Grant A, Malone-Moses M, Manheimer E. Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke: trial reanalysis adjusted for baseline imbalances. BMJ Evid Based Med. 2020 Oct;25(5):168-171. doi: 10.1136/bmjebm-2020-111386. Epub 2020 May 19.
Bluhmki E, Chamorro A, Davalos A, Machnig T, Sauce C, Wahlgren N, Wardlaw J, Hacke W. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol. 2009 Dec;8(12):1095-102. doi: 10.1016/S1474-4422(09)70264-9. Epub 2009 Oct 21.
Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008 Sep 25;359(13):1317-29. doi: 10.1056/NEJMoa0804656.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
135.312
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.